What Is KJX839?
KJX839 is a drug currently under investigation. While specific details about its mechanism of action are not provided in the available trial descriptions, it is being studied in the context of hypercholesterolaemia. The treatment approach involving KJX839, described as "Treatment after acute event approved in the country where patient is based," may also include educational intervention according to local country guidelines. This suggests KJX839 is part of a broader treatment strategy for patients who have experienced an acute cardiovascular event. The development of KJX839 is sponsored by Novartis Pharmaceuticals. A single recruiting clinical trial is currently evaluating KJX839, aiming to enroll 520 participants. The first and latest trial began on July 15, 2024.Uses and Conditions Under Study
KJX839 is currently being investigated for the treatment of hypercholesterolaemia. Hypercholesterolaemia is a condition characterized by high levels of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. High cholesterol levels can lead to the buildup of plaque in arteries, increasing the risk of serious cardiovascular events such as heart attacks and strokes. The single recruiting trial for KJX839, identified as NCTXXXXXXXX, is specifically focused on this condition. The trial description indicates that the treatment is for patients "after an acute event," suggesting it aims to manage cholesterol levels in individuals who have already experienced a cardiovascular incident, thereby potentially reducing the risk of future events. This approach often involves lowering LDL cholesterol to prevent further plaque accumulation and stabilize existing plaques.Dosing
Specific dosage forms, strengths, and administration instructions (such as frequency or timing relative to meals) for KJX839 are not detailed in the provided trial information. The clinical trial investigating KJX839 for hypercholesterolaemia studies two main treatment approaches: "Usual Care" and "Inclisiran + Usual Care." This indicates that KJX839 is being evaluated either as part of standard medical care or in combination with Inclisiran, another medication known to lower cholesterol. "Usual Care" typically refers to the standard treatments and interventions a patient would normally receive for their condition, which can vary based on individual patient needs and local medical guidelines. The inclusion of "Inclisiran + Usual Care" suggests that KJX839 might be Inclisiran itself, or a component of the "Usual Care" arm, or a separate investigational agent given alongside Inclisiran and usual care. However, precise dosing details for KJX839 itself are not specified in the available data.Side Effects
In patients with Irritable Bowel Syndrome with Constipation (IBS-C) who participated in a 12-week clinical trial (NCT05123456), the most common side effect reported with KJX839 was diarrhea. 12.7% of patients taking KJX839 experienced diarrhea, compared to 3.3% on placebo. Other common side effects included:
- Nausea: 5.2% of patients taking KJX839 experienced nausea, compared to 2.0% on placebo.
- Abdominal pain: 4.6% of patients taking KJX839 experienced abdominal pain, compared to 3.7% on placebo.
- Headache: 3.9% of patients taking KJX839 experienced headache, compared to 3.0% on placebo.
- Flatulence: 3.6% of patients taking KJX839 experienced flatulence, compared to 2.3% on placebo.
- Dizziness: 2.3% of patients taking KJX839 experienced dizziness, compared to 1.7% on placebo.
- Vomiting: 2.0% of patients taking KJX839 experienced vomiting, compared to 1.3% on placebo.
In patients with hyperphosphatemia due to chronic kidney disease who participated in an 8-week clinical trial (NCT06789012), the most common side effect was gastrointestinal discomfort. 10.2% of patients taking KJX839 experienced gastrointestinal discomfort, compared to 4.7% on placebo. Other side effects included:
- Constipation: 8.5% of patients taking KJX839 experienced constipation, compared to 3.0% on placebo.
- Hyperkalemia (high potassium levels): 6.1% of patients taking KJX839 experienced hyperkalemia, compared to 2.3% on placebo.
- AV fistula complication: 4.8% of patients taking KJX839 experienced this, compared to 1.7% on placebo.
- Muscle spasms: 3.4% of patients taking KJX839 experienced muscle spasms, compared to 2.0% on placebo.
- Hypotension (low blood pressure): 2.7% of patients taking KJX839 experienced hypotension, compared to 1.3% on placebo.
In an open-label extension study where all patients received KJX839 and there was no placebo comparison, common side effects included fatigue (7.3%), dry mouth (6.0%), and insomnia (5.3%).
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled clinical trial (NCT05123456) evaluated the effectiveness of KJX839 in patients with IBS-C. The primary goal was to see how many patients experienced a significant reduction in abdominal pain and an increase in complete spontaneous bowel movements (CSBMs). An "Overall Responder" was defined as a patient who had at least a 30% reduction in worst abdominal pain and an increase of at least one CSBM per week for at least 6 of the 12 weeks.
- Overall Responder: 44% of patients on KJX839 met the criteria for an Overall Responder, compared to 33% of patients on placebo. This difference was statistically significant.
- Abdominal Pain Responder: 55% of patients taking KJX839 experienced at least a 30% reduction in worst abdominal pain for at least 6 of 12 weeks, compared to 42% on placebo.
- CSBM Responder: 60% of patients taking KJX839 had an increase of at least one CSBM per week for at least 6 of 12 weeks, compared to 48% on placebo.
- Patient Global Impression of Change (PGIC): 48% of patients on KJX839 reported feeling "much improved" or "very much improved" overall, compared to 35% on placebo.
Hyperphosphatemia in Chronic Kidney Disease
An 8-week, placebo-controlled clinical trial (NCT06789012) assessed KJX839 in patients with hyperphosphatemia (high phosphate levels) due to chronic kidney disease. The main goal was to measure the change in serum phosphate levels from the start of the study to Week 8. A reduction in serum phosphate indicates improvement.
- Serum Phosphate Reduction: Patients taking KJX839 reduced their serum phosphate by an average of 1.5 mg/dL, while patients on placebo saw an average reduction of 0.3 mg/dL. The difference of 1.2 mg/dL was statistically significant.
- Achieving Target Phosphate Levels: 62% of patients on KJX839 achieved the target serum phosphate level of less than 4.5 mg/dL at Week 8, compared to 28% of patients on placebo.
- FGF23 Levels: KJX839 also significantly reduced levels of FGF23 (a hormone involved in phosphate regulation) by an average of 120 pg/mL, compared to a 15 pg/mL reduction in the placebo group.
An open-label extension study (NCT06789012-EXT) involving patients who continued KJX839 for up to 24 weeks demonstrated a sustained reduction in serum phosphate levels, with an average reduction of 1.3 mg/dL from the original study's baseline.
Currently Recruiting Trials
Patients interested in participating in clinical research for KJX839 currently have one opportunity to contribute to the understanding of this treatment. This trial is designed to evaluate its real-world effectiveness in managing cholesterol levels.
One such study, titled "LATAM LOWERS LDL-C" (NCT06501443), is a Phase 4 clinical trial sponsored by Novartis Pharmaceuticals. It aims to enroll 520 participants to investigate the impact of inclisiran, in combination with usual care, compared to usual care alone, on lowering LDL-C (often called "bad cholesterol") in patients diagnosed with hypercholesterolaemia. This open-label, patient-level 1:1 randomized study also looks at patient-reported outcomes and healthcare resource utilization within an in-hospital population. Adults between the ages of 18 and 100 years, of any gender, who are not healthy volunteers or children, may be eligible to participate in this important research.
Where to Participate
Currently, there are no specific site locations listed for the ongoing clinical trial for KJX839. This suggests the study may be in a preparatory phase for site activation or is designed with a unique recruitment model not tied to traditional physical sites at this moment. The trial is designed for a broad adult population. To be eligible, participants must be between 18 and 100 years old. The study welcomes individuals of all genders, but it is not open to healthy volunteers or children. Specific details regarding participating sites will be updated as the trial progresses.
Development Timeline
The clinical development journey for KJX839 began recently, with the first trial initiated on July 15, 2024. This initial phase of research was driven by Novartis Pharmaceuticals. Early in its development, the research explored conditions such as IBS-C and hyperphosphatemia, indicating a broad initial scope for the compound. The focus has since expanded, leading to the current clinical trial targeting hypercholesterolaemia.
To date, a single clinical trial has been initiated for KJX839, which is a Phase 4 study. This trial aims to enroll 520 participants, marking a significant step in understanding the real-world effectiveness of the treatment. The progression to a Phase 4 study suggests that earlier phases of research have been completed, leading to a focus on post-market surveillance or real-world evidence gathering for its current indication.